Cancer immunotherapy: Car T Cell Technology

A type of treatment in which a patient’s T cells (a type of immune cell) are altered in the laboratory so they will bind to cancer cells and destroy them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which eliminates the white blood cells, including the T cells, and directs the rest of the blood back to the patient. Then, the gene for a special receptor named a chimeric antigen receptor (CAR) is introduced into the T cells in the laboratory. Millions of the CAR T cells are developed in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and destroy them.

 

  • CAR-T cell therapy in Acute Lymphoblastic Leukaemia
  • CAR-T cells therapy in Chronic Lymphocytic Leukaemia
  • CAR-T cell in Multiple Myeloma

Related Conference of Cancer immunotherapy: Car T Cell Technology

November 25-26, 2024

7th International Conference on Anti-Cancer Drugs & Therapies

Vancouver, Canada
November 28-29, 2024

14th World Congress on Breast Cancer

Paris, France
December 10-11, 2024

8th Global Meeting on Oncology and Radiology

Dubai, UAE
December 11-12, 2024

34th Experts Meet On Cancer Research & Therapy

Paris, France
December 12-13, 2024

44th Euro Congress on Cancer Science & Therapy

Rome, Italy
March 10-11, 2025

3rd World Congress on Oral Cancer

Paris, France
March 24-25, 2025

25th World Congress on Cancer and Diagnostics

London, UK
March 24-25, 2025

10th World Conference on Breast and Cervical Cancer

Paris, France
June 16-17, 2025

26th World Congress on Cancer Summit

Amsterdam, Netherlands

Cancer immunotherapy: Car T Cell Technology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in